Bio-Techne logo

TECH - Bio-Techne Share Price

$356.59 0.9  0.3%

Last Trade - 22/01/21

Large Cap
Market Cap £10.06bn
Enterprise Value £10.09bn
Revenue £555.1m
Position in Universe 740th / 6630
Unlock TECH Revenue
Relative Strength (%)
1m +7.08%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -1.35%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
452.2 499 563 643 714 738.7 847.6 950.5 +10.3%
+5.2 -5.0 -13.6 +28.4 -12.3 +97.4 +1.68 +16.9
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 30 September 2020,BIO-TECHNE Corp revenues increased 11% to $204.2M. Netincome applicable to common stockholders increased from$14.3M to $33.4M. Revenues reflect Protein Sciences segmentincrease of 10% to $154.4M, Diagnostics and Genomicssegment increase of 18% to $50.1M, United States segmentincrease of 11% to $113.6M, U.K segment increase of 11% to$43.1M, Greater China segment increase of 12% to $18.1M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for TECH
Graphical History


TECH Revenue Unlock TECH Revenue

Net Income

TECH Net Income Unlock TECH Revenue

Normalised EPS

TECH Normalised EPS Unlock TECH Revenue

PE Ratio Range

TECH PE Ratio Range Unlock TECH Revenue

Dividend Yield Range

TECH Dividend Yield Range Unlock TECH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TECH EPS Forecasts Unlock TECH Revenue
Profile Summary

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.

Last Annual June 30th, 2020
Last Interim September 30th, 2020
Incorporated July 17, 1981
Public Since February 9, 1989
No. of Shareholders: 55,000
No. of Employees: 2,300
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P 400 Mid Cap , Nasdaq Composite , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 38,609,307
Free Float (0.0%)
Eligible for
TECH Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for TECH
Upcoming Events for TECH
Tuesday 2nd February, 2021 Estimate
Q2 2021 Bio-Techne Corp Earnings Release
Wednesday 28th April, 2021 Estimate
Q3 2021 Bio-Techne Corp Earnings Release
Frequently Asked Questions for Bio-Techne
What is the Bio-Techne share price?

As of 22/01/21, shares in Bio-Techne are trading at $356.59, giving the company a market capitalisation of £10.06bn. This share price information is delayed by 15 minutes.

How has the Bio-Techne share price performed this year?

Shares in Bio-Techne are currently trading at $356.59 and the price has moved by 63.01% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bio-Techne price has moved by 39.42% over the past year.

What are the analyst and broker recommendations for Bio-Techne?

Of the analysts with advisory recommendations for Bio-Techne, there are there are currently 3 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bio-Techne is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Bio-Techne next release its financial results?

Bio-Techne is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Bio-Techne dividend yield?

The Bio-Techne dividend yield is 0.36% based on the trailing twelve month period.

Does Bio-Techne pay a dividend?

Last year, Bio-Techne paid a total dividend of 1.28, and it currently has a trailing dividend yield of 0.36%. Looking ahead, Bio-Techne has not announced an ex-dividend date yet.

When does Bio-Techne next pay dividends?

Bio-Techne has yet to annouce their ex-dividend date. The historic dividend yield on Bio-Techne shares is currently 0.36%.

How do I buy Bio-Techne shares?

To buy shares in Bio-Techne you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bio-Techne?

Shares in Bio-Techne are currently trading at $356.59, giving the company a market capitalisation of £10.06bn.

Where are Bio-Techne shares listed? Where are Bio-Techne shares listed?

Here are the trading details for Bio-Techne:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: TECH
What kind of share is Bio-Techne?

Based on an overall assessment of its quality, value and momentum, Bio-Techne is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bio-Techne share price forecast 2021?

Shares in Bio-Techne are currently priced at $356.59. At that level they are trading at 7.86% premium to the analyst consensus target price of 0.00.

Analysts covering Bio-Techne currently have a consensus Earnings Per Share (EPS) forecast of 5.769 for the next financial year.

How can I tell whether the Bio-Techne share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bio-Techne. Over the past six months, the relative strength of its shares against the market has been 11.01%. At the current price of $356.59, shares in Bio-Techne are trading at 31.91% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bio-Techne PE Ratio?

The Bio-Techne PE ratio based on its reported earnings over the past 12 months is 55.67. The shares are currently trading at $356.59.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Bio-Techne?

Bio-Techne's management team is headed by:

Robert Baumgartner - CHM
John Higgins - IND
Roeland Nusse - IND
Charles Kummeth - PRE
James Hippel - CFO
David Eansor - CEX
Brenda Furlow - SVP
Alpna Seth - IND
Joseph Keegan - IND
Kim Kelderman - CEX
Julie Bushman - IND
Who are the major shareholders of Bio-Techne?

Here are the top five shareholders of Bio-Techne based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.11% (3.52m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 8.93% (3.45m shares)
Brown Capital Management, LLC Investment Advisor
Percentage owned: 3.96% (1.53m shares)
Baron Capital Management, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.87% (1.50m shares)
Neuberger Berman, LLC Investment Advisor/Hedge Fund
Percentage owned: 3.36% (1.30m shares)
Similar to TECH
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.